Last updated: July 3, 2026
Hospira Inc. v. Amneal Pharmaceuticals LLC (1:15-cv-00697): Litigation Summary, Patent-Impact Analysis, and Generic Entry Risk
Hospira Inc. v. Amneal Pharmaceuticals LLC, No. 1:15-cv-00697, is a Hatch-Waxman patent litigation in which Hospira sought to block Amneal’s proposed generic under the Orange Book framework. The record reflects a Paragraph IV posture typical of ANDA-driven cases, with the key commercial outcome determined by (1) which asserted Orange Book patents were held infringed/valid and (2) the resulting FDA approval and settlement or launch timing.
Because the request is limited to litigation summary and analysis for this specific docket, only high-confidence facts from the case record should be reported; no dossier-level patent list, claims construction outcome, or final disposition is provided in the prompt. If those case-record details are not available in the provided materials, the response must not fabricate them.
What is Hospira Inc. v. Amneal Pharmaceuticals LLC (1:15-cv-00697) about?
The case name and docket number indicate a patent-infringement dispute tied to FDA ANDA activity. In practice, suits under this caption typically involve Hospira as the reference product/patent owner and Amneal as the ANDA applicant, with allegations focused on one or more Orange Book-listed patents via Paragraph IV certifications under 21 U.S.C. § 355(j).
What procedural posture matters in 1:15-cv-00697?
Featured litigation drivers in ANDA Paragraph IV cases usually include:
- Asserted Orange Book patents and the specific causes of action pled (infringement, invalidity).
- Claim construction outcomes that determine infringement exposure.
- Injunctive relief requests that control whether a generic can enter pre-exclusivity or pre-judgment.
These case-specific details are not present in the prompt.
Which patents were asserted in Hospira v. Amneal, and what claims were at issue?
ANDA-driven cases tied to Orange Book listings typically assert:
- Drug substance patents (API synthesis, polymorphs, salts).
- Composition/formulation patents (stabilizers, buffers, pH systems, excipient blends).
- Method-of-use patents (if applicable to the reference listed drug).
The prompt does not include the asserted patent numbers, expiration dates, or claim themes for 1:15-cv-00697. Without that, a complete and accurate patent-and-claim analysis cannot be produced.
How did the court handle infringement and validity in Hospira v. Amneal?
Patent litigation outcomes hinge on:
- Whether the court found infringement under the asserted claims.
- Whether the court found the patents invalid (anticipation/obviousness under 35 U.S.C. §§ 102/103, or other statutory grounds).
- Whether any asserted claims were excluded via claim construction or summary judgment.
No findings, rulings, or final disposition dates are provided in the prompt. Reporting would require the opinion/order text or a docket event summary.
Did Hospira and Amneal settle, and what did the settlement affect?
In Hatch-Waxman cases, a settlement can:
- Permit launch of the generic on a date certain.
- Carve out specific patents (design-around or license structure).
- Include a consent judgment that frames which patents remain enforceable.
No settlement terms, consent judgments, or launch dates are provided in the prompt, so a reliable settlement analysis cannot be completed.
What is the litigation timeline for 1:15-cv-00697?
A litigation timeline normally includes:
- Complaint filing date and service.
- Initial ANDA-related procedural steps (often aligned to FDA notice windows).
- Docket milestones: Markman/claim construction, dispositive motions, trial if any.
- Final judgment or dismissal/entry of consent judgment.
- Appellate actions, if filed.
No event-by-event docket dates are included in the prompt.
How does 1:15-cv-00697 affect Amneal’s generic entry risk?
Generic entry risk in this docket would depend on:
- Remaining enforceable patents after any partial summary judgments or claim-construction outcomes.
- Whether any non-infringement or invalidity rulings were final.
- Whether a settlement or adjudication triggered an FDA launch approval timing.
The prompt does not include the adjudicated or settled patent set, so risk quantification cannot be accurate.
What regulatory pathway was implicated (ANDA, Paragraph IV), and what Orange Book status would have driven the suit?
In Hospira vs. Amneal filings of this style, the suit is typically tied to:
- An ANDA for a small-molecule drug product.
- A Paragraph IV certification to one or more Orange Book patents.
- A 30-month stay mechanism under 21 U.S.C. § 355(j)(5)(B) that affects launch timing until a court decision or settlement.
The specific drug, the Orange Book listed patents, and the certification details are not included in the prompt.
How strong is the Hospira patent estate in this dispute?
Patent estate strength is evaluated by:
- How many patents were asserted versus how many survived.
- Claim scope and whether courts adopted a narrow or broad construction.
- Invalidity defenses and whether anticipation/obviousness theories succeeded.
No asserted-patent list and no court outcomes are present, so the strength assessment would be speculative.
Compare Hospira’s enforcement posture versus Amneal’s defenses in 1:15-cv-00697
In Paragraph IV litigation, plaintiffs typically argue:
- The ANDA product infringes under a proper construction.
- Prior art does not render claims obvious or anticipated.
Defendants typically counter with:
- Non-infringement and non-qualification of claim limitations.
- Invalidity based on prior art combinations or lack of novelty.
Case-specific pleadings and rulings are not provided, so a credible compare-and-contrast analysis cannot be generated.
What manufacturing or design-around constraints could result from the court’s rulings?
If the court found infringement, design-around typically turns on:
- Formulation changes (buffers/pH, stabilizers, container/closure, particle size).
- Process changes for drug substance.
- Use of different salt forms/polymorph control strategies.
If the court found non-infringement, design-around may be less necessary.
But no infringement findings are included in the prompt.
Does the case have downstream effects for other competitors?
Depending on the outcome:
- Other ANDA filers for the same reference product may face similar asserted-patent enforcement.
- A settlement can sometimes create broader ecosystem timing effects if the reference listed drug patents are narrowed or effectively resolved.
No details on any co-defendants, consolidations, or estoppel effects are provided.
Key Takeaways
- Hospira Inc. v. Amneal Pharmaceuticals LLC (1:15-cv-00697) is an ANDA-style Hatch-Waxman patent dispute signaled by the party captions and docket format.
- The prompt does not provide the asserted patent numbers, court rulings, or the final disposition required for a complete litigation summary and patent-impact analysis.
- Without case-record specifics (opinions/orders, settlement terms, or docket events), reporting beyond the docket identification would risk inaccuracy.
FAQs
- Is Hospira v. Amneal (1:15-cv-00697) a Paragraph IV ANDA case or a different type of dispute?
- What impact does a 30-month stay have on generic launch timing in this docket?
- Which Orange Book patents were asserted in 1:15-cv-00697, and what were their expiration dates?
- Did any appeal or remand occur after the district court’s decision in 1:15-cv-00697?
- What formulation or process design-around options are typically used after an infringement finding in Hospira-style enforcement actions?
References
- United States District Court docket for Hospira Inc. v. Amneal Pharmaceuticals LLC, No. 1:15-cv-00697.
